The new adjuvant chemotherapy combined with research on the effects of patients with gastric cancer before operation of the nutrition supportenteral

Objective To evaluate the effect of neoadjuvant chemotherapy combined with enteral nutrition support treatment for improving the effect on immune function and nutritional status in patients with gastric cancer, gastric resection for clinical implementation preparation. Method According to the order of treatment to 50 cases of gastric cancer patients in our hospital department of general surgery were divided into treatment group and control group, 25 cases in each group. Control group were treated with neoadjuvant chemotherapy(m FOLFOX6), patients in treatment group based on control group, were given enteral nutrition preparation.. Two groups of patients after three courses of treatment implemented gastric resection. Observed two groups before treatment and after treatment of 3 courses of immune index, nutrition indicators improved conditions and the occurrence of adverse reactions. Result Two groups of patients before treatment CD4, CD8, CD4/CD8, natural killer(NK) cells levels showed no significant difference(P 0.05); patients treated before and after treatment of these indicators were significant differences(P 0.05), control group of patients before and after treatment showed no significant(P 0.05); treatment group patients CD4, CD4/CD8, NK cells levels were significantly higher, CD8 cells were significantly lower than control group, and the differences were statistically significant(P 0.05); total protein, albumin, prealbumin, transferrin, haemoglobin, weight, in two groups before treatment had no significant difference(P 0.05); before and after treatment, patients in treatment group had significant differences in NPS score(P 0.05), other nutritional indicators showed no significant difference(P 0.05); after treatment, total protein, albumin, prealbumin, transferrin, hemoglobin, NPS score, body weight in treatment group were significantly higher than control group, the differences were statistically significant(P 0.05); appetite, eating choked, bloating, nausea and other adverse events in treatment group were significantly lower than control group, the differences were statistically significant(P 0.05). Conclusion Patients with gastric cancer before neoadjuvant chemotherapy combined with enteral nutrition support treatment is beneficial to the enhancement of immune level, improve the nutritional status and chemotherapy tolerance, ready for operation, to alleviate symptoms in patients, which is of great significance in improving the quality of life, worthy of clinical application.